Aprea Therapeutics, Inc. (APRE)

NASDAQ: APRE · USD

$0.53

+0.01 (+2.4%)· Recorded snapshot

Market cap	6.6M
Revenue (ttm)	5.2K
Net income (ttm)	-12.3M
EPS (ttm)	-$0.60
Shares out	12.6M
Volume	143,616
Beta	1.63

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 5.2K
Net income (ttm): -12.3M
EPS (ttm): -$0.60
Market cap: 6.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Conserver

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-46.1

P25 n/aP50 n/aP75 n/a

ROIC-31

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All APRE indicators

Market & fundamental data

Available fields

184

Groups with data

Currency

USD

Showing 184 of 184 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001781983
Company name	Aprea Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	03836J201
Earnings date	2026-11-11
Earnings time	bmo
Employees	8
Employees change	1
Employees growth	14.29%
Enterprise value	$-34.6M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2006
Industry	Biotechnology
IPO date	2019-10-03
Is primary listing	Yes
Is SPAC	No
ISIN number	US03836J2015
Last 10-K release date	2026-03-16
Last earnings date	2026-08-12
Last refreshed	2026-10-28
Last stock split date	2023-02-13
Last stock split type	Reverse
Market cap	$6.6M
Market cap category	Nano-Cap
Next earnings date	2026-11-11
Options	No
Price	$0.53
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	APRE
U.S. state	Pennsylvania
Website	https://aprea.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-113.69%
FCF / EV yield	35.38%
FCF yield	-179.29%
P/B ratio	0.17x
P/S ratio	1,310.6x
Price / tangible book value	0.18x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-255,025.52%
Pretax margin	-237,362.8%
Profit per employee	$-1.5M
Revenue per employee	$648
ROA	-27.73%
ROCE	-33.73%
ROE	-46.15%
ROIC	-30.99%
SBC / revenue	8,989.18%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	10
EPS growth years	3
Net income growth years	3
Revenue growth	-99.38%
Revenue growth 3Y	-72.51%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-15,400
Depreciation and amortization	$22,032
EBIT	$-13.2M
EBITDA	$-13.2M
EPS	$-0.60
FCF per share	$-0.97
Financing cash flow	$36.9M
Free cash flow	$-12.2M
Free cash flow minus SBC	$-12.6M
Gross profit	$-6.7M
Investing cash flow	$-15,400
Net cash flow	$24.7M
Net income	$-12.3M
Operating cash flow minus SBC	$-12.6M
Operating income	$-13.2M
Revenue	$5,185
Stock-based compensation	$466,089

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-9.6
Book value per share	$3.10
Debt / equity	0
Long-term assets	$376,810
Long-term liabilities	$0
Net cash (debt)	$41.2M
Net cash / market cap	606.78%
Net cash growth	149.41%
Net debt / equity	-1.05
Piotroski F-Score	2
Property, plant and equipment	$64,033
Shareholders' equity	$39.2M
Tangible book value	$38.5M
Tangible book value per share	$3.10
Total assets	$42.3M
Total cash	$41.2M
Total debt	$0
Total liabilities	$3.1M
WACC	13.21%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0
Current assets	$41.9M
Current liabilities	$3.1M
Current ratio	13.55
Net working capital	$-2.4M
Quick ratio	13.33
Working capital	$38.8M
Working capital turnover	0

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-243.85%
Dividend yield	0%
Shareholder yield	-243.85%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$0.75
1D price change	2.36%
1M price change	-30.98%
1M total return	-30.98%
1W price change	-6.28%
1W total return	-6.28%
1Y price change	-60.81%
1Y return CAGR	-60.84%
1Y total return	-60.81%
20-day SMA	$0.58
200-day SMA	$0.76
3M price change	-15.94%
3M total return	-15.94%
3Y price change	-85.16%
3Y return CAGR	-47.05%
3Y total return	-85.16%
50-day SMA	$0.70
50-day SMA vs 200-day SMA	50under200
52-week high	$1.49
52-week high date	2026-01-30
52-week low	$0.41
52-week low date	2026-10-26
6M price change	-39.02%
6M total return	-39.02%
All-time high	$25.80
All-time high date	2022-07-19
All-time low	$0.41
All-time low date	2026-10-26
Average true range (ATR)	$0.06
Average volume	248.8K
Beta (1Y)	3.2
Beta (2Y)	2.2
Beta (5Y)	1.63
Change from 52-week high	-64.76%
Change from 52-week low	28.07%
Change from all-time high	-97.96%
Change from all-time low	28.07%
Change from open	0.36%
Day's gap	1.99%
Dollar volume	$75,413
High price	$0.53
Low price	$0.52
Monthly RSI	31.82
Open price	$0.52
Position in 52-week range	95%
Premarket change	1.37%
Premarket close	$0.51
Premarket price	$0.52
Previous close	$0.51
Price vs 150-day SMA	-30.1%
Price vs 20-day SMA	-10.05%
Price vs 200-day SMA	-30.64%
Price vs 50-day SMA	-25.28%
Relative volume	0.58
Return from IPO price	-96.4%
RSI	39.42
Sharpe ratio	-0.56
Sharpe ratio (3Y)	-0.49
Sortino ratio	-0.82
Sortino ratio (3Y)	-0.71
Volume	143.6K
Weekly RSI	35.98
YTD price change	-38.44%
YTD total return	-38.44%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	7.9M
Float percentage	62.77%
Shares change (QoQ)	264.19%
Shares change (YoY)	243.85%
Shares held by insiders	8.98%
Shares held by institutions	11.57%
Shares outstanding	12.6M
Short % of float	7.86%
Short % of shares	4.93%
Short ratio	2.5 days

Deeper analysis on APRE

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this APRE report

Is a complete APRE research report available?

No complete published report is available for Aprea Therapeutics, Inc. (APRE) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Aprea Therapeutics, Inc. (APRE)

Price

Financial snapshot

Fair-value bridge

Latest news · APRE

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All APRE indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on APRE

Frequently asked questions